Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 813267

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Godman, Brian; Malmström, RE; Diogene, E; Gray, A; Jayathissa, S; Timoney, A; Acurcio, F; Alkan, A; Brzezinska, A; Bucsics, A et al.
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? // Expert Review of Clinical Pharmacology, 8 (2015), 1; 77-94 doi:10.1586/17512433.2015.990380 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 813267 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Autori
Godman, Brian ; Malmström, RE ; Diogene, E ; Gray, A ; Jayathissa, S ; Timoney, A ; Acurcio, F ; Alkan, A ; Brzezinska, A ; Bucsics, A ; Campbell, SM ; Czeczot, J ; de Bruyn, W ; Eriksson, I ; Yusof, FA ; Finlayson, AE ; Fürst, J ; Garuoliene, K ; Guerra Júnior, A ; Gulbinovič, J ; Jan, S ; Joppi, R ; Kalaba, M ; Magnisson, E ; McCullagh, L ; Miikkulainen, K ; Ofierska-Sujkowska, G ; Pedersen, HB ; Selke, G, Sermet, C ; Spillane, S ; Supian, A ; Truter, I ; Vlahović-Palčevski, Vera ; Vien, LE ; Vural, EH ; Wale, J ; Władysiuk, M ; Zeng, W ; Gustafsson, LL.

Izvornik
Expert Review of Clinical Pharmacology (1751-2433) 8 (2015), 1; 77-94

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
clinical pharmacology ; critical drug evaluation ; dabigatran ; differential pricing ; ivacaftor ; managed entry agreements ; new models ; rational use of medicines ; sofosbuvir ; trastuzumab emtansine

Sažetak
Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium- priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi- criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita



POVEZANOST RADA

Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka,
Fakultet zdravstvenih studija u Rijeci

Profili:

Avatar Url Vera Vlahović-Palčevski (autor)

Poveznice na cjeloviti tekst rada:

doi www.tandfonline.com

Citiraj ovu publikaciju:

Godman, Brian; Malmström, RE; Diogene, E; Gray, A; Jayathissa, S; Timoney, A; Acurcio, F; Alkan, A; Brzezinska, A; Bucsics, A et al.
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? // Expert Review of Clinical Pharmacology, 8 (2015), 1; 77-94 doi:10.1586/17512433.2015.990380 (međunarodna recenzija, članak, znanstveni)
Godman, B., Malmström, R., Diogene, E., Gray, A., Jayathissa, S., Timoney, A., Acurcio, F., Alkan, A., Brzezinska, A. & Bucsics, A. (2015) Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. Expert Review of Clinical Pharmacology, 8 (1), 77-94 doi:10.1586/17512433.2015.990380.
@article{article, author = {Godman, Brian and Malmstr\"{o}m, RE and Diogene, E and Gray, A and Jayathissa, S and Timoney, A and Acurcio, F and Alkan, A and Brzezinska, A and Bucsics, A and Campbell, SM and Czeczot, J and de Bruyn, W and Eriksson, I and Yusof, FA and Finlayson, AE and F\"{u}rst, J and Garuoliene, K and Guerra J\'{u}nior, A and Gulbinovi\v{c}, J and Jan, S and Joppi, R and Kalaba, M and Magnisson, E and McCullagh, L and Miikkulainen, K and Ofierska-Sujkowska, G and Pedersen, HB and Spillane, S and Supian, A and Truter, I and Vlahovi\'{c}-Pal\v{c}evski, Vera and Vien, LE and Vural, EH and Wale, J and W\ladysiuk, M and Zeng, W and Gustafsson, LL.}, year = {2015}, pages = {77-94}, DOI = {10.1586/17512433.2015.990380}, keywords = {clinical pharmacology, critical drug evaluation, dabigatran, differential pricing, ivacaftor, managed entry agreements, new models, rational use of medicines, sofosbuvir, trastuzumab emtansine}, journal = {Expert Review of Clinical Pharmacology}, doi = {10.1586/17512433.2015.990380}, volume = {8}, number = {1}, issn = {1751-2433}, title = {Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?}, keyword = {clinical pharmacology, critical drug evaluation, dabigatran, differential pricing, ivacaftor, managed entry agreements, new models, rational use of medicines, sofosbuvir, trastuzumab emtansine} }
@article{article, author = {Godman, Brian and Malmstr\"{o}m, RE and Diogene, E and Gray, A and Jayathissa, S and Timoney, A and Acurcio, F and Alkan, A and Brzezinska, A and Bucsics, A and Campbell, SM and Czeczot, J and de Bruyn, W and Eriksson, I and Yusof, FA and Finlayson, AE and F\"{u}rst, J and Garuoliene, K and Guerra J\'{u}nior, A and Gulbinovi\v{c}, J and Jan, S and Joppi, R and Kalaba, M and Magnisson, E and McCullagh, L and Miikkulainen, K and Ofierska-Sujkowska, G and Pedersen, HB and Spillane, S and Supian, A and Truter, I and Vlahovi\'{c}-Pal\v{c}evski, Vera and Vien, LE and Vural, EH and Wale, J and W\ladysiuk, M and Zeng, W and Gustafsson, LL.}, year = {2015}, pages = {77-94}, DOI = {10.1586/17512433.2015.990380}, keywords = {clinical pharmacology, critical drug evaluation, dabigatran, differential pricing, ivacaftor, managed entry agreements, new models, rational use of medicines, sofosbuvir, trastuzumab emtansine}, journal = {Expert Review of Clinical Pharmacology}, doi = {10.1586/17512433.2015.990380}, volume = {8}, number = {1}, issn = {1751-2433}, title = {Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?}, keyword = {clinical pharmacology, critical drug evaluation, dabigatran, differential pricing, ivacaftor, managed entry agreements, new models, rational use of medicines, sofosbuvir, trastuzumab emtansine} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.